A Phase II, controlled clinical study designed to evaluate the effect of ArtemiC in patients diagnosed with COVID-19 - ArtemiC

MGC Pharmaceuticals Ltd0 个研究点目标入组 10 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1. Confirmed SARS-CoV-2 infection.
•2. Hospitalized patient with COVID-19 of moderate stable or worsening severity not requiring ICU admission, and on the other hand not experiencing clinical improvement under ongoing standard care.
•3. Age: 18 years old and above.
•4. Subjects must be under observation or admitted to a controlled facility or hospital (home quarantine is not sufficient).
•5. Ability to receive treatment by spray into the oral cavity

•1. Tube feeding or parenteral nutrition.
•2. Oxygen requirements beyond use of nozzles or simple mask as per score 4
•3. Respiratory decompensation requiring mechanical ventilation.
•4. Uncontrolled diabetes type 2.
•5. Autoimmune disease.
•6. Pregnant or lactating women.
•7. Need for admission to ICU in the course of the present hospitalization at any time prior to completion of the recruitment to the study.
•8. Any condition which, in the opinion of the Principal Investigator, would prevent full participation in this trial or would interfere with the evaluation of the trial endpoints.

发起方